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Essential Medicines symposium speakers (from l to r) Prof. Peter Danchin,
Ambassador Necton D. Mhura, Prof. Diane Hoffmann and Prof. Leslie Meltzer Henry

On October 29-30, 2015, Law & Health Care Professor Leslie Meltzer
Henry, along with colleagues Diane Hoffmann and Peter Danchin, Director
of the Maryland Carey Law's International and Comparative Law Program,
organized a unique symposium that brought together legal academics, IRB
members, and medical researchers from North America and southern Africa
for an “International Symposium on Clinical Trials and Access to Essential
Medicines in African Countries.” The symposium, co-sponsored by the
Faculty of Law at Chancellor College in Malawi, examined ethical and legal
challenges to developing and distributing essential medicines for diseases
such as HIV and malaria in African countries.
The symposium was the latest in a long collaboration between Maryland
Carey Law and the Faculty of Law at Chancellor College in Malawi which
began in 2010 when University of Maryland, Baltimore’s (UMB) Center
for Global Education Initiatives sent an interprofessional team of faculty
and students to Malawi to study the health and legal needs of orphans and
vulnerable children. The Honorable Necton D. Mhura, Ambassador from
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Malawi to the United States, opened the roundtable by recounting the
history of the collaboration. In the summer of 2013, Hoffmann and
Danchin traveled to Malawi and worked with Malawian law professor
Chikosa Banda to organize a workshop for students and faculty from
both universities on the subject of HIV/AIDS. Since that time, faculty
members from both schools have conducted visits and workshops in both
Baltimore and Malawi.
Professor Henry was brought into the Essential Medicines symposium
because of her expertise and her extensive scholarship on clinical
research ethics. Based on her work in this area, she is frequently asked to
provide expert commentary for federal and local agencies, organizations,
and the media on ethical issues that arise in human subjects research.
She has also served as a bioethics consultant for the Department of
Defense and has presented to panels of experts at the Department of
Health and Human Services, the Food and Drug Administration (FDA),
and the National Institutes of Health Bioethics Advisory Committee.
Professor Henry is also a core faculty member at the Johns Hopkins
Berman Institute of Bioethics. Her recent scholarship in this area ranges
from compensation for research subjects who sustain research-related
injuries and commentary on changes to the Common Rule. She also
teaches both the survey and advanced bioethics courses at the law school.
Selected Articles by Professor Leslie Meltzer Henry
• Respect and Dignity: A Conceptual Model for Patients in the
Intensive Care Unit, 5.1A Narrative Inquiry in Bioethics 5A
(2015) (with C. Rushton, M.C. Beach, and R. Faden).
• Just Compensation: A No-Fault Proposal for Research-Related
Injuries, Journal of Law & the Biosciences (2015).
• Moral Gridlock: Conceptual Barriers to No-Fault Compensation
for Injured Research Subjects, 41 Journal of Law, Medicine &
Ethics 411 (2013).
• Revising the Common Rule: Prospects and Challenges, 41
Journal of Law, Medicine & Ethics 386 (2013).
Henry’s interest in international human subjects research is largely
focused on what researchers from the United States owe host countries
and research subjects in those countries based on the International
Ethical Guidelines for Biomedical Research Involving Human Subjects
published by the Council for International Organizations of Medical
Sciences (CIOMS). The guidelines, published in 2002, provide guidance
on the ethical justification and scientific validity of research, ethical
review of research, and informed consent, among other topics. Her
expertise in this area added greatly to the conference planning.
The four collaborators – Henry, Hoffmann, Danchin and Banda –
organized the conference around four panels:
1) Access to Essential Medicines as a Human Right;
2) The Law and Ethics of Clinical Trials: What Rules Should
Govern Clinical Research in Africa;
3) What do Clinical Researchers and Sponsors Owe to Host
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Communities?;
4) Legal Regimes and Obstacles: Free Trade,
Intellectual Property, and Access to Medicine.
Each panel was composed of an interprofessional
and international group of speakers who shared their
academic and personal perspectives of conducting
research in southern Africa where such research brings
both enormous promise and the potential for grave
ethical conflicts.
Professor Henry moderated the third panel on
the responsibilities of clinical researchers to host
communities. Research conducted in lower income
countries often involves ethical issues that are more
complex than in developed countries because of
power differentials, lack of health care outside of
clinical trials, and the potential for exploitation of
research subjects. Professor Henry’s panel discussed
several frameworks that aim to create more equitable
interactions between researchers and participants and
host communities. Joining her on the panel were Dr.
Joseph Mfutso-Bengo, Professor of Bioethics and
Director of the Centre for Bioethics at the University
of Malawi College of Medicine and Dr. David
Wendler, Head of the Section on Research Ethics in
the Department of Bioethics at the National Institutes
of Health. Both Dr. Mfutso-Bengo and Dr. Wendler
have written extensively on these topics and brought
perspectives from both sides of the Atlantic.
The first issue tackled by Professor Henry’s panel
related to the interpretation of the requirement to
provide “reasonable availability” of any product
developed during the trial to the host country/
research population. The idea of making interventions
reasonably available emerged in 1993 from guidelines
issued by CIOMS (and later strengthened in 2002).
The guidelines stress that the sponsoring agency
conducting the research should make any product
developed through the research “reasonably available”
to the community in which the research is conducted.
How these guidelines should be interpreted –
including such issues as who should make the
decision as to what is reasonable and what constitutes
“available” – was tackled by the panelists and others.
Professor Henry’s panel members also discussed the
issues of ancillary care obligations, or obligations to
provide care to research participants that is not related
to the research question, and the provision of “fair
benefits,” another ethical framework for research.
The fair benefits framework requires that research
be conducted in developing countries only if three
conditions are met: 1) the research addresses a health

problem of the developing country population, 2) the
research objectives provide a strong justification for
conducting the research in the chosen community, and
3) the research poses few risks to the participants or
the benefits to them clearly outweigh the risks.

Conference Speakers, Moderators
& Supporters
Chikosa Banda, Professor, Faculty of Law at
Chancellor College in Malawi
Mark Barnes, Partner, Ropes & Gray, LLP
Danwood Chirwa, Professor, University of Cape
Town Law Faculty
Peter Danchin, Professor and Director of the
International and Comparative Law Program,
University of Maryland Carey School of Law
Sean Flynn, Associate Director, Program on
Information Justice and Intellectual property,
American University Washington College of Law
Lisa Forman, Assistant Professor, University of
Toronto
Diane Hoffmann, Professor and Director of
the Law & Health Care Program, University of
Maryland Carey School of Law
Heinz Klug, Professor and Director, Global Legal
Studies Center, University of Wisconsin
Miriam Laufer, Associate Professor, University
of Maryland School of Medicine
Joseph Mfutso-Bengo, Professor of Bioethics and
Director of the Centre for Bioethics, University of
Malawi College of Medicine
The Honorable Necton D. Mhura, Malawian
Ambassador to the United States
Victor Mwapasa, Associate Professor, University
of Malawi College of Medicine
Seema Shah, Faculty Bioethicist, NIH*
Hilda Kaluwa Soko, Law Lecturer, University of
Malawi Chancellor College of Law
David Wendler, Senior Investigator and Head of
the Section on Research Ethics, NIH
Lucie White, Professor, Harvard Law School
*Ms. Shah was unable to attend the conference, but her
remarks were given by David Wendler

The symposium was supported by the UMB Center for
Global Education Initiatives, Alan & Nancy Eason, the
Stuart Rome Lecture Fund, the Reuben Shiling Mental
Health Law Fund, the Leonard C. Homer/Ober|Kaler
Law and Health Care Fund, and the Dr. Richard H.
Heller Fund.
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Other Collaborations
In addition to organizing the Essential Medicines
symposium this year, Professor Henry has been
working intensively as a co-investigator on two
projects relating to the ethical conduct of medical
research. The first project is an NIH-funded, multiyear project called PHASES (Pregnancy & HIV/
AIDS: Seeking Equitable Study), which is designed
to establish ethically and legally acceptable strategies
for conducting research about HIV treatment and
prevention during pregnancy. Henry’s collaborators
include Ruth Faden at the Johns Hopkins Berman
Institute of Bioethics, Maggie Little at Georgetown’s
Kennedy Institute of Ethics, Annie Lyerly at the
University of North Carolina, and Anna Mastroianni at
the University of Washington School of Law.
The project was created to address a gap in the
diagnosis and treatment needs of pregnant women, a
key population affected by HIV/AIDS. In November
2014, the PHASES team met with former FDA
regulators, pharmaceutical company representatives,
IRB chairs, and legal academics to begin the process
of creating an ethical framework that would permit
research with pregnant women with HIV. Research
under the PHASES grant has been conducted in the
United States to date, but the research team recently

received four more years of funding to continue their
research in South Africa, Botswana and Malawi. The
PHASES team is currently conducting engagement
meetings at these sites with community members,
local investigators, and local IRBs.
Henry and her PHASES collaborators also
were recently funded by the Wellcome Trust to
develop ethical and legal guidance for conducting
research with pregnant women during public health
emergencies, like the Zika crisis, where there is
an urgent need to attend to the health needs of
pregnant women and their offspring. The project is
called “Conducting Ethical Research with Pregnant
Women in the Emerging Zika Pandemic and Beyond:
Challenges Arising in Public Health Crises.” The goals
of the project are to engage key experts in order to
understand the needs and challenges of conducting
research on women whose pregnancy may be affected
by Zika and to develop a framework to conduct
research with this population. The project will include
working with medical researchers to determine when
research requires participation of pregnant women and
what the barriers are to conducting such research in
certain target countries. Ultimately the team hopes to
create guidance documents intended to be of real-time
utility in the Zika crisis and future public health crises.

Professor Ellen Weber: Front and Center on Protection
of Individuals with Mental Health and
Substance Use Disorders
The Drug Policy Clinic at University of Maryland
Carey Law is working to address Maryland’s heroin
and prescription drug problem by helping individuals
gain access to health insurance coverage and tackling
systemic barriers to drug treatment. The Clinic
was created by Professor Ellen Weber to address
practices that inhibit the expansion of drug treatment
in communities and the criminal justice system and
that discriminate against individuals with histories
of drug dependence. To identify the most pressing
client issues, the Clinic established medical-legal
partnerships (MLPs) at two Baltimore drug treatment
programs – Man Alive and Institutes for Behavior
Professor Ellen Weber
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Resources in August 2015. Both programs provide
methadone maintenance treatment and outpatient
counseling services to hundreds of patients with
substance use disorders, and offer “health homes” for
patients with Medicaid who have multiple chronic
health issues. Two student teams from the clinic
assisted patients with problems obtaining Medicaid or
private insurance coverage and accessing health care.
They also looked for system-wide standards that could
be the source of client problems. Weber described the
value of this type of advocacy clinic to law students
- “the collaboration has exposed our students to the
complex financing system for drug treatment, and they
have learned to help patients navigate multiple public
and private health insurance programs.”
Both teams quickly learned that patients with
Medicare coverage face significant barriers accessing
drug treatment, particularly methadone maintenance
treatment. The teams launched several projects to
assist patients, including identifying those who were
eligible for programs that reduce the cost of Medicare
premiums and prescription drugs. Student-attorneys
Brenda Kathurima and James Cook also conducted
training programs about Medicare coverage to help
program administrators assist patients and to educate
policymakers about the need to secure stable funding
for the growing population of patients with Medicare
coverage.
Man Alive identified a group of patients who
should have been able to use their private secondary
insurance policy – often a retiree policy – to cover
their drug treatment, but faced administrative
barriers imposed by both the Center for Medicare
and Medicaid Services (CMS) and private carriers.
Student-attorneys Isabel Coello and Mike Martin
worked with the clients and the program’s clinical and
administrative staff to document treatment and claims
histories and then make the case to insurance carriers
that the private policies should pay outstanding and
future claims. The team’s efforts have resulted in
positive outcomes for each client. The carriers have
reimbursed over $4300 in unpaid claims, some dating
back many months, and are now paying all claims
without delay. The team has also developed a toolkit
that will help treatment programs around the state
address these reimbursement issues for their patients.
The Clinic has also helped individuals with private
insurance challenge discriminatory reimbursement
decisions and advocate for better enforcement of

the federal Mental Health Parity and Addiction
Equity Act. One hospital-based treatment program
discovered that a national insurance carrier had
repeatedly denied reimbursement for methadone
treatment services for patients with both individual
and small employer plans sold on the State’s health
benefit exchange. Student-attorney Kris Corwin has
represented one patient whose plan denied coverage
for methadone treatment in violation of state law. In
the course of his investigation, Kris identified plan
standards that impose more restrictive utilization
review requirements for substance use and mental
health treatment than for medical services. The
Clinic reported these potential Parity Act violations
to the Maryland Insurance Administration, which has
launched an investigation of the carrier’s practices.
In the meantime, the carrier admitted, in response to
the Clinic’s insurance appeal, that it had incorrectly
denied coverage for the client’s methadone treatment.
The carrier reimbursed the methadone clinic $2700 for
the client’s care.
The Drug Policy Clinic has also identified Parity
Act violations in the Maryland Medical Assistance
program and has looked to the Maryland General
Assembly to require compliance. Beginning in
September 2014, the Clinic and its partners began to
work with the State’s Medicaid officials to develop
a comprehensive substance use disorder benefit that
complied with the Parity Act. When discussions failed
to resolve outstanding benefit problems, the Clinic
drafted legislation (HB 1217/SB 899), introduced
in the 2016 legislative session, to require the State
to bring its Medicaid benefit into compliance with
federal law. The Clinic and its partners advocated
successfully with members of the General Assembly,
resulting in overwhelming support and passage of the
bills. The State is required to adopt regulations by
July 1, 2017 and those standards should result in more
comprehensive services for the State’s most vulnerable
youth and adults.
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Professor Karen Rothenberg Creates Unique
NIH Field Placement for Health Law Students
The four students were placed in different
offices in NIH and NHGRI: the Technology
Transfer Office, the Division of Genomics and
Society, the Department of Bioethics at the NIH
Clinical Center, and the Social and Behavioral
Research Branch with the Senior Advisor for
Genomics and Health Disparities. Their diverse
research projects included the ethical and legal
implications of the use of legacy samples, gene
editing, the Precision Medicine Initiative, and
health disparities in access to designer drugs.
The students spent two days a week at NIH in
Bethesda, Maryland attending Undiagnosed
Diseases Program rounds and NHGRI
Institutional Review Board (IRB) meetings,
conducting research and writing memos for
their supervisors and developing an extensive
Dr. Eric Green, Director, NHGRI Speaks to Professor Rothenberg’s
written research project.
Externship Students
The four students divided their time between
working with their NHGRI supervisors and
In Fall 2015, Law & Health Care Program faculty
participating in the accompanying workshop with
member and former Dean of the law school, Karen
Professor Rothenberg. The purpose of the split
Rothenberg, created an opportunity for four students
structure was to introduce students to the day-toto work and study at the National Institutes of Health
day work of NIH lawyers, to provide a structured
(NIH) through a new externship program that, based
opportunity for students to share their experiences, and
on its positive response, she will lead again in Fall
to allow students to explore more deeply the ethical,
2016. Rothenberg, a national expert in the ethical,
legal, social and policy challenges raised by genomics
legal and social implications of genetic testing and
research. The students were also required to keep
genomic research, developed the externships with
a weekly journal reflecting on their participation in
colleagues at NIH whom she met during her four
clinical rounds, their weekly assignments with their
years as Senior Advisor to the Director of Genomics
supervisors, and research related to research projects.
& Society at the National Human Genome Research
Apurva Dharia (3L), who was placed in the
Institute (NHGRI). Rothenberg is now back at
NHGRI Technology Transfer Office, reflected on the
Maryland Carey Law and continues to serve as a
experience, “I was able to work closely with and learn
Visiting Scholar in the Department of Bioethics at
from the licensing and technology transfer specialists
NIH’s Clinical Center. According to Rothenberg, the
within the National Human Genome Research
externship program “provides a unique opportunity for Institute. As part of my experience I was able to draft
law students to experience the making of health policy licensing and transfer agreements, catalogue NIH
at the most prestigious medical research institution
patent portfolios, and research important bioethics
in the world while having opportunities to delve into
and intellectual property issues related to the cutting
cutting edge research topics at the intersection of
edge of genomics research. As part of an incredibly
ethics, law, and science. In addition to working with
enlightening externship and workshop we were
world renowned health policy makers, the students
privileged to learn from the Nation's foremost experts
had the opportunity to round in the Clinical Center
in bioethics in genomics research.”
and meet the patients who hope to benefit from the
advances in genomics research.”
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Law & Health Care Program Celebrates 30th Anniversary
with “Health Law: Past, Present, and Future” Panels

Sanford Teplitzky, Joanne Pollak (’76), Adjunct Prof. Jack Schwartz and Prof. Leslie Meltzer Henry (from l to r)

On October 30, 2015, the Law & Health Care
Program celebrated its 30th anniversary with a panel
discussion on “Health Law: Past, Present, and Future”
followed by a gala celebration in the law school’s
historic Westminster Hall. The panel discussion gave
120 program alumni and local health law practitioners
the chance to hear from experts in different areas of
health law about how health law has changed over the
years from a loosely to a highly regulated industry,
where we are now with the Affordable Care Act
(ACA), and the way in which biotechnology and big
data promise to transform the health care industry
– and the field of health law – in the future. At the
reception and celebration, attendees listened to a
staged reading of a bioethics play written by Professor
Karen Rothenberg and a song written by adjunct
Professor Jaime Doherty and his law partner Jeff
Pecore that revealed the more lighthearted side of the
L&HCP.
The “Health Law: Past, Present, and Future” event
started with a look back at how health law was studied
and practiced a generation ago. The panelists who
spoke about “Health Law: Past” were Joanne Pollak
’76, Senior Vice President and General Counsel at
Johns Hopkins Medicine, Sanford "Sandy" Teplitzky,
Principal at Ober|Kaler, and Jack Schwartz, Adjunct
Professor and former Maryland Assistant Attorney

General and Director of Health Policy Development
at the Maryland Office of the Attorney General. With
questions from L&HCP Professor Leslie Meltzer
Henry, all three panelists agreed that they “stumbled”
into the practice of health law largely because it was
not an established field of study or practice when
they started their legal careers. Courses in Law &
Psychiatry or Forensic Medicine existed, but beyond
these meager offerings, the panelists described their
providential entrance into health law by accepting law
firm and governmental positions in which they were
tasked with some aspect of regulation of the health
care industry.
Pollak described learning about the regulation of
the health care industry as a young lawyer at Piper
& Marbury (now DLA Piper) when three important
pieces of legislation were passed in Maryland– the
Maryland Certificate of Need Law (1969), the
law establishing the Maryland Health and Higher
Educational Facilities Authority (1970) and the Health
Services Cost Review Commission law (1971).
These early regulatory laws trained Pollak in the
complexities of the health care industry which have
formed the basis of her career largely as counsel for
Johns Hopkins Medicine.
Working on complex end-of-life care cases that
arose in the 1970s when he worked at the Maryland
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Office of the Attorney General set the stage for
Schwartz’s career as an expert in law and bioethics,
particularly end of life care and the right of patients to
refuse life sustaining treatment. Teplitzky and Pollak
also described their work on early informed consent
cases. Pollak recalled arguing a case at the bedside of
a patient who did not consent to life saving treatment.
Pollak argued – and the judge agreed – that the 1977
Sard v. Hardy case (379 A.2d 1014) that established
the standard for informed consent in Maryland also
provided patients with the option not to consent
to medical treatment. The panel agreed that these
informed consent cases and Jehovah’s Witnesses cases
during the same time period fundamentally changed
patients’ relationships with their doctors. Finally,
Teplitzky talked about the evolution of the nation’s
body of fraud and abuse laws that also grew up in the
last thirty years. His early work at the US Department
of Health and Human Services in the office that
supported the Medicare program led to a long career
developing and interpreting fraud and abuse laws,
which he now does at the law firm of Ober/Kaler.
The second panel was moderated by L&HCP
Professor Ellen Weber and focused on current issues in
health law through a Maryland lens. Panelists Carolyn
Quattrocki, Executive Director of the Maryland Health
Benefit Exchange, and Peter Parvis ’77, a Partner at
Miles & Stockbridge, focused on recent changes to
Maryland’s unique Medicare waiver and Affordable
Care Act implementation in Maryland.
Under Maryland's “old” waiver which came into
place in the mid-1970s, Parvis explained, Maryland
hospitals received a waiver from federal Medicare
payment methods (i.e., diagnostic related groups) if
all payers were charged the same rate for services and
the cumulative growth in Maryland inpatient payments
was less than the growth of US government inpatient
payments. This system was designed to ensure that
uninsured patients were not charged the full amount
for medical services but rather charged the negotiated
rates paid by insurance companies. It also kept rates
reasonably related to costs which, for many years,
led to the lowest “markup” in the country for medical
services. Parvis explained that Maryland has moved
to a new waiver program that started January 1, 2014
as a five-year demonstration project. Under this new
“global budgeting” waiver program, each Maryland
hospital’s total annual revenue and reimbursement
amount will be known at the beginning of the fiscal
year based on historic data adjusted to account for

Prof. Amanda Pustilnik, David Cade (’85), Marcus Wang ('08)
and Prof. Frank Pasquale (from l to r)

inflation. The program limits the annual increase
in total per capita hospital costs in Maryland to less
than 3.58%. This program is designed to focus on
population health, prevention, and cost savings by
including measures that reduce readmissions, avoid
preventable hospitalizations and complications, and
increase wellness programs.
Ms. Quattrocki described the “big decisions” that
shaped Maryland’s implementation of the ACA. As
soon as the law was passed, Maryland’s Governor set
up a task force that determined that the state should
be a national leader in ACA implementation, expand
Medicaid, and create a robust quasi-public health
insurance exchange. Despite early computer problems
that stalled the roll out of the exchange, as of October
2015, the reforms brought 750,000 people into either
private insurance or Medicaid and decreased the
percentage of uninsured from 10.9% of the population
to approximately 4.9%.
Finally, the attendees were galvanized by the
discussions of the “Future” panel. Speaking on the
panel were L&HCP faculty members Frank Pasquale
and Amanda Pustilnik, as well as prominent alumni
David Cade ’85, CEO of the American Health
Lawyers Association, and Marcus Wang ’08, CoFounder of ZytoGen, LLC, a preimplantation genetic
diagnosis company. Professor Diane Hoffmann,
who moderated the panel, started off by asking
Cade to comment on the biggest issues that would
face health lawyers in the next decade. Looking
toward the future, Cade noted that the health law
issues that are likely to grow in prominence are
regulation of privacy and data security, big data
and data analytics, and digital technology such as
mobile medical applications. Professor Pasquale, a

8 │ Law & Health Care Newsletter

nationally-recognized big data expert, followed up
on this point and urged the gathered health lawyers to
defend professional autonomy from being overtaken
by technology. He explained the risk that predictive
analytics and pattern recognition may lead people to
conclude that professional judgement is not necessary
for physicians to diagnose and treat illness. The
automation of disability determinations would also
challenge fundamental rights to due process and
undermine claimants’ dignity. Based on his research
on big data, predictive analytics, and artificial
intelligence in fields where these technologies are
more advanced, Pasquale believes lawyers need to be
involved in their deployment in health care settings,
to assure they are accurate, ethically sound, and
economically fair across socioeconomic groups.
Professor Pustilnik, an expert in the intersection of
the law and neuroscience, spoke about technology as
a new frontier for lawyers that will require all of us
to understand the law in new ways and to question if
current law is adequate to address the legal and ethical
issues that new technologies bring. Pustilnik focused
on the use of neuroscience tools to diagnose and
understand pain. Historically no tools have existed to
measure pain and when the cause of pain is not clear
physicians and legal bodies do not know how to assess
it. The experience of pain has legal ramifications in
terms of disability compensation, determination of
tort damages, and health insurance benefits (among
other things) but it is often poorly understood by the
judicial and administrative bodies that encounter it.
Misunderstanding of pain is particularly common
when it is unrelated to an injury or separate disease
state. Chronic pain that is not peripheral to another
condition is often typically treated as a psychiatric
disorder although neuroscience technologies are now
able to demonstrate that chronic pain causes – and is
caused by – changes in brain function. Pustilnik hopes
to see pain considered a neurological disease from
a medical, legal, and policy perspective. Pustilnik
was recently invited to join a working group of the
International Association for the Study of Pain to
develop international standards for the legal uses of
brain imaging.
Finally, Marcus Wang focused his comments on
the promises and potential ethical complications of
reproductive technologies. Although he sees the clear
benefit of providing parents the opportunity to select
healthy embryos for implantation, he is aware that the
ability to control which embryo becomes a child raises

challenging ethical issues especially at the macro level
where overuse of the technology could lead to gender
imbalance and elimination of certain conditions and
disabilities.
The give-and-take between panelists and audience
highlighted the tension between the great promise of
technology, its attendant ethical and legal dilemmas,
as well as the clear role of lawyers to help ensure that
an appropriate and just balance is reached between the
two.
The evening – with its scholarly conversations and
celebratory moments – was a reflection of the dream
that Professor Karen Rothenberg had when she started
the L&HCP in 1983. Four years later, Diane Hoffmann
left a practice at Dewey Ballantine to help forge
new ties with the health sciences on the University
of Maryland, Baltimore campus. By 1988, the law
school had 11 courses in everything from Civil Rights
of Individuals with Disabilities to Legal and Ethical
Issues in Biotechnology. The program now boasts 11
faculty members and has graduated over 400 students
with the Certificate in Health Law.

Prof. Karen Rothenberg, L&HCP Director Diane Hoffmann
and L&HCP Managing Director Virginia Rowthorn
(from l to r)

Adjunct Professor Jamie Doherty and Jeff Pecore
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Health Law Students Partner with Mississippi Center for
Justice during Annual Service Trip
by: Reena Palanivel and Allison Best
(2016 Trip Leaders)

Mississippi Center for Justice team and MD Carey Law Health Law students discuss research projects

Maryland Carey Law students have been traveling
since early 2006 to the Gulf region of the United
States to help with the vast need for legal services
created by Hurricane Katrina. In 2009, the Law
& Health Care Program (L&HCP) approached the
Mississippi Center for Justice (MCJ) in Jackson about
creating a trip that focused on health law. MCJ has
a well-established health law practice in Jackson and
in the northern Delta region of Mississippi focused
primarily on access to health care and the legal needs
of individuals with HIV disease. Since 2010, groups
of 10-12 health law students have spent a week in
Mississippi during winter break working closely with
MCJ attorneys on outreach and advocacy efforts.
On this year’s annual Health Law trip, Maryland
Carey Law students had the opportunity to work on
several projects focused on HIV/AIDS advocacy and
the Affordable Care Act in the Jackson, Mississippi
region. To kick off the week, the group of twelve
health law students visited a transitional group home
for individuals living with HIV/AIDS in inner city
Jackson. The residents of the home shared stories of
the biggest challenges they have faced since learning
of their diagnosis. In response to questions on a legal
needs screening tool administered by the students,
the residents identified the areas of the law that still
need the most improvement. Every resident agreed
that ending the stigma surrounding HIV/AIDS is the
most important step to ensuring individuals can live
well with HIV/AIDS and in ending the epidemic,
altogether.
In addition to visiting the group home, half of the

health law students worked on research projects
focused directly on the prevalence and impact of HIV/
AIDS on different groups around Mississippi. One
project focused on exploring how HIV/AIDS impacts
the Latino population in Mississippi, many of whom
are undocumented and do not have consistent access
to health care. Another group compared HIV/AIDS
statistics between Mississippi and Arkansas in order
to identify which outreach strategies and programs
have had the best outcomes on improving access to
HIV/AIDS testing and medical care. The third group
researched medical-legal partnerships that work with
community health centers to improve access to care.
The Mississippi Center for Justice plans to use all of
the data and information collected by the Maryland
Carey Law health law students to prepare its agenda
for the coming year and adjust its focus to cover the
unmet legal needs of low-income Mississippians.
The second project required legal research,
data collection, and brainstorming ideas on the
implementation of the Affordable Care Act. The deep
south is an area in the country that has high poverty
rates which correlates with a high number of uninsured
individuals. Some of the major issues involve lack of
understanding of the Affordable Care Act, awareness
of the state’s provisions and benefits, and services for
health care. For this project, the students compiled
data regarding the uninsured rates in the state of
Mississippi and observed the correlation between
different federal poverty levels. They also researched
the Medicaid enrollment centers in the Delta, mapped
out the eighty-four centers and discovered the very
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limited days and times per month that individuals can
visit them. Lastly, the students identified outreach
and education organizations that the MCJ could team
up with in order to teach families how to enroll their
children into the Children's Health Insurance Program
(CHIP). The research project will help the Mississippi
Center for Justice focus on outreach and advocacy to
increase the number of insured individuals in the state.
Throughout the week, the Maryland Carey Law
students enjoyed experiencing Mississippi’s culture.
The students were able to explore not only the city
of Jackson, but also the more rural Delta area. They

toured the Mississippi State Capitol and had the
opportunity to meet with several congressmen. They
met representatives of different health organizations
and collaborated on ideas on how to improve the
health system in the state. Finally, they ate delicious
southern comfort food, listened to jazz music, and
toured the BB King Museum. The Health Law trip
provided the Maryland Carey Law students with an
amazing, first-hand opportunity to learn about critical
issues in health law in a rural setting very different
from their home in Baltimore.

Professors Pasquale and Hoffmann Focus on
Social Media and Risk Management
On January 13, 2016, the Maryland/DC Society for Healthcare Risk
Management and the Maryland Bar Association co-sponsored a conference at
the law school titled “When Worlds Collide: The Intersection of Healthcare,
Law & Technology.” Director of the L&HCP Diane Hoffmann helped
organize the event which was developed with two themes in mind – the
demonstrations related to the death of Freddie Gray and the role of social
media and technology in health care. The symposium was attended by over
200 local risk managers and focused on four topics: the Public Behavioral
Health Crisis; Medical and Policy Implications of Mental and Behavioral
Health; Social Media and Privacy in Healthcare; and Anticipating Patient
and Legal Risks Associated with Emerging Technology. The first two
Professor Frank Pasquale
panels focused on heightening awareness of the specific issues faced by law
enforcement officers when responding to individuals who are experiencing
a behavioral or emotional health crisis. These challenges in the field are then exacerbated by the lack of
behavioral health resources and the lack of acute care beds and outpatient services for the behavioral health
patient populations. The second two panels brought together risk managers, hospital attorneys and legal
academics to discuss the unique challenges that technology brings to the provision of health care.
Professor Hoffmann moderated the Social Media and Privacy in Healthcare panel which included L&HCP
Professor Frank Pasquale, a national expert in social media and health care privacy. Pasquale has an active
Twitter presence with 11,700 followers at @FrankPasquale and is a contributing member of the Concurring
Opinions blog which focuses on a broad range of legal topics including big data and social media issues. The
panel looked at access by the media to information about a breaking story or newsworthy event involving
an individual who becomes a patient at the hospital and how the hospital can get better control over the
social media that is put out about such individuals or the hospital more generally. The panelists – a former
television producer who now works in communications at a university, a hospital attorney and Pasquale –
looked at the issue from their professional perspectives. Tim Parsons, now Director of Communications
at Johns Hopkins Carey School of Business, spoke about his experience trying to get news from hospitals
as a television producer and also, in his current role, acting as a gatekeeper of information from the
media. Pamela Rayne, Associate Senior Counsel at Johns Hopkins Health System, spoke about navigating
between the needs of the media and the legal needs of the hospitals and patients. Professor Pasquale
discussed the kinds of things that have gotten on to social media that perhaps should not have and he related
some problematic legal cases and news stories in which health care providers shared patient images or
information on social media. Finally Pasquale suggested some policies that health care providers might
want to think about for employees/staff as to their use of social media.
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Hoffmann and Co-Investigators Bring Together
Working Group to Discuss Regulation of
Microbiota Transplantation

Microbiota Transplantation Co-Investigators after May meeting

This year, in December and again in May, Diane
Hoffmann, Director of the Law & Health Care
Program (L&HCP) and her University of Maryland
Baltimore (UMB) co-investigators held meetings
supported by their NIH-funded grant, “Microbiota
Transplantation: Recommendations for a Regulatory
Framework.” As we reported in a prior newsletter,
in June 2015, the UMB team was awarded a grant
from the National Institute for Allergy and Infectious
Diseases (NIAID) to study the legal and regulatory
aspects of a cutting edge medical treatment called
microbiota transplantation (MT). MT is the
transplantation of communities of microorganisms
from one individual to another. The two-year grant
is facilitating a project to study regulatory options for
fecal microbiota transplantation and other emerging
MT options including vaginal, skin, anterior nares,
oral, and whole body microbiome transplants.
At present, there is much interest and increasing
evidence-based support for one type of MT - fecal

microbiota transplantation (FMT) - which involves
the transplantation of fecal material obtained from a
healthy individual into the gastrointestinal tract of a
patient recipient to treat disease. FMT has been found
particularly effective in treating recurrent Clostridium
difficile infection (CDI), a virulent infection that
causes inflammation of the colon and deadly diarrhea.
According to the CDC, CDI causes almost half a
million infections among patients in the United States
every year. In 2011, approximately 29,000 patients
died within 30 days of the initial diagnosis of CDI
and of those, about 15,000 deaths were estimated
to be directly attributable to CDI putting it among
one of the top causes of infectious disease death in
the United States. It is the most common microbial
cause of healthcare-associated infections in US
hospitals and costs up to $4.8 billion each year in
excess health care costs for acute care facilities alone.
More than 80 percent of the deaths associated with
CDI occurred among Americans aged 65 years or
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older. Importantly, one out of every five patients with
healthcare-associated CDI experience a recurrence of
the infection.
FMT is used to treat patients with recurrent CDI
who, in the past, had few treatment options. Before
FMT was clinically available – and still to this day –
desperate patients have resorted to “do-it-yourself”
FMT at home in some cases relying on YouTube
videos that provide detailed instructions. According
to Catherine Duff, Executive Director of The Fecal
Transplant Foundation, a nonprofit that is advocating
for safer, more widespread access to the treatment,
about 10,000 people perform at-home FMT in the
United States each year, notwithstanding the infection
risk associated with sharing stool.
As physicians have started to provide FMT to
patients with recurrent CDI, stool banks have opened
to provide fecal material to physicians performing
FMT. While there are a number of stool banks in
hospitals, larger stool banks have opened, including
OpenBiome in Cambridge, MA and Advancing Bio
in California, that provide screened frozen fecal
material ready for clinical use. In addition, various
applications of microbiome-based products to treat
CDI and other conditions are currently being studied
by pharmaceutical companies and biotechnology startups, such as Seres Health, Rebiotix, and Repoopulate,
that are developing specially-designed biotherapeutic
products that treat CDI and other conditions by
transferring microbial communities or cocktails to
a recipient via enema, colonoscopy or orally in pill
form.
The Food and Drug Administration (FDA) is
actively considering how to regulate FMT. At present,
FDA classifies FMT as a procedure involving live
biotherapeutics (a category of drugs), but is exercising
“enforcement discretion” for recurrent CDI if the
donor is known to the recipient and if adequate
informed consent is obtained from the patient. On
March 1, 2016, FDA issued another draft guidance
document on FMT which does not alter FDA’s current
enforcement discretion policy. While the March
2016 draft guidance does not include the requirement
that the donor be known to the recipient, it states that
FMT may be used for recurrent CDI if “the FMT
product is not obtained from a stool bank.” The draft
guidance explicitly states that stool banks must have
an IND application in place before distributing FMT
product but – importantly – under the new guidance

an IND sponsor may request a waiver of certain IND
regulations when it is providing FMT product to
doctors treating patients with recurrent CDI. FDA
is using the new March 2016 guidance to solicit
feedback on this general proposal, and on which
parts of the IND application would be appropriate to
waive.
Under the grant, the co-investigators put together
a working group of approximately 30 expert
stakeholders including scientists, clinicians, patient
and professional association advocates, bioethicists,
academics, lawyers, and individuals from the
biotechnology industries who have an interest in
microbiota transplantation or expertise relevant to the
project. In addition, representatives of FDA and NIH
participate as observers.
At the first meeting in December, prominent
microbiome researchers who are part of the working
group discussed the microbiota communities that
reside in the gut, vagina, nasal and oral cavities,
and skin and the status and gaps in research about
microbiota transplantation in those body sites. The
working group also studied potential frameworks for
regulation of FMT including the existing frameworks
for blood and tissue. At the May meeting, the working
group went beyond regulation of FMT and considered
how vaginal and oral microbiota transplantation
should be regulated by comparing the critical
similarities and differences raised by transferring
these microbial communities at different body sites.
For instance, studies show that increased microbial
diversity in the gut confers a health benefit, whereas
a healthy vaginal tract is associated with colonization
by a single Lactobacillus bacteria. The working
group considered this and other differences that
might influence how different forms of MT should be
regulated.
At the May meeting, Dr. Rob Knight, a prominent
microbiome researcher at University of California
San Diego spoke to the working group via Skype
regarding cutting edge research conducted by principal
researcher Dr. Maria Dominguez-Bello, a New York
University School of Medicine faculty member. In
what some call a “whole body microbiome transplant”
researchers swabbed babies born by Cesarean section
with gauze covered in their mothers' vaginal fluids.
The concept is to confer the microbial communities
the baby would have received if it had been born via
the birth canal. The transfer of maternal microbial

13 │ Law & Health Care Newsletter

communities is thought to help babies’ immune
systems develop. Only a small proof-of-concept study
has been conducted to date, but there is excitement
about this form of MT and the working group will
consider how it should be regulated along with other
forms of MT. Dr. Knight also discussed the potential
use of MT to treat malnourished infants whose gut

microbiota may not be able to recover from the effects
of malnutrition, thus leading to long-term negative
health sequelae.
The working group will meet for the third and final
time in December 2016 to finalize recommendations
that will appear in a white paper.

UMB Microbiota Transplantation Investigators
• Diane Hoffmann, Law & Health Care Program, University of Maryland Carey School of Law
(Principal Investigator)
• Dr. Frank Palumbo, Center on Drugs and Public Policy, University of Maryland School of Pharmacy
• Dr. Jacques Ravel, Institute for Genome Sciences, University of Maryland School of Medicine
• Dr. Mary-Claire Roghmann, Department of Epidemiology and Public Health, University of
Maryland School of Medicine
• Dr. Erik von Rosenvinge, Division of Gastroenterology, University of Maryland School of Medicine
and Veterans Affairs Maryland Health Care System
• Virginia Rowthorn, Law & Health Care Program, University of Maryland Carey School of Law
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“Freddie Gray’s Baltimore” – a New Course Designed to
Teach and Heal

On April 12, 2015, Freddie Carlos Gray, Jr., a
25-year-old African American was arrested by
the Baltimore Police Department for possessing a
switchblade. While being transported in a police
van, Gray fell into a coma and died from injuries
to his spinal cord. Mr. Gray was not secured inside
the van while driving to the police station. On May
1, 2015, the Baltimore City State's Attorney filed
charges against six police officers after the medical
examiner’s report ruled Gray's death a homicide on
the grounds that Gray had died as a result of a 'rough
ride'—a form of police brutality in which a victim
is helplessly thrown around the interior of a police
vehicle by deliberately abrupt police driving. The
incident caused demonstrations in Baltimore primarily
among African Americans who wanted to express
their anguish about the specific incident and decades
of inequitable treatment on a multitude of fronts. In
response to the palpable distress of the city in the
aftermath of the incident, eleven Maryland Carey
Law faculty members, including Law & Health Care
Program faculty members Michael Greenberger
(course master), Diane Hoffmann, and Deborah
Weimer, developed an 8-week course called Freddie
Gray’s Baltimore: Past, Present and Moving Forward
to help students at the University of Maryland Schools
of Law and Social Work explore the causes of, and
possible solutions to, the unrest in Baltimore.
The course attracted almost 100 law and social work
students as well as extensive media coverage when
it was introduced in Fall 2015. The class was held
in the law school’s largest lecture hall and its leaders
still needed to turn away applicants. The course was
offered again in Spring 2016 at the law school as
well as to undergraduate students at the University of
Maryland in College Park.
The course focused on social, economic and other
issues facing the citizens of Baltimore, including

policing practices, criminal justice, access to housing,
health care, education, joblessness and community
development. Professor Hoffmann organized the class
module that discussed the intersection of poverty and
health and worked with health law faculty members
Deborah Weimer, Ellen Weber and Sara Gold to
create a class that explained the impact of the social
determinants of health (including socioeconomic
status, education, the physical environment,
employment, and social support networks) in
Baltimore. During the fall class, Dr. Leana S. Wen,
the City of Baltimore’s Health Commissioner,
spoke to the class about her efforts to improve the
health of Baltimore’s residents which she sees as a
critical cornerstone of well-being and social justice.
Following Dr. Wen’s talk, the faculty team arranged
for a “standardized patient” to interact with students.
The “patient” was an actor taking on the role of a
resident of the Sandtown Winchester neighborhood of
Baltimore which suffers from a high level of poverty
and need and was the home of Freddie Gray. Students
interacted with the patient regarding her health care
needs and were able, through the stories she related,
to understand the impact of her life’s challenges on
her health and her ability to access health care. After
hearing from the patient, the students were asked
how they as lawyers or social workers could help
the patient in ways that might affect her health. The
takeaway message for the students was that the law
itself can be a social determinant of health.
The Freddie Gray course arose from conversations
among law school faculty about how to help students
understand the many issues raised by Freddie Gray’s
death. The course is intended to be a springboard for
further student and faculty involvement in citizen and
government efforts to reform law and policy for the
benefit of the city and beyond.
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Law & Health Care Program
500 West Baltimore Street
Baltimore, MD 21201
www.law.umaryland.edu/healthlaw
Comments and letters should be
forwarded to the above address.

Support the Law & Health Care Program
The Law & Health Care Program has hosted a number of hallmark meetings and roundtables to bring
together health care practitioners, legal academics, medical experts, scientists, and policymakers to
examine cutting-edge issues in health policy, law, or ethics. Over the next 30 years, we hope to count you
as a partner in this effort. We plan to build on the stellar foundation we have created as health law educators
to keep asking questions and pushing the field of health law forward. In order to do this, we are asking for
your support. Every contribution helps our program achieve its goals.
There are two ways to give to the Law & Health Care Program:
~ Online at http://www.law.umaryland.edu/give/healthlaw
~ Mail, by sending a check made payable to: UMBF, Inc./ Law & Health Care
to 620 West Lexington Street, 2nd Floor, Baltimore, MD 21201
Funds for the Law & Health Care Program are administered by the University of Maryland, Baltimore Foundation, Inc.
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